Your browser doesn't support javascript.
loading
Cost-effectiveness of acromegaly treatments: a systematic review.
Leonart, Letícia P; Borba, Helena H L; Ferreira, Vinicius L; Riveros, Bruno S; Pontarolo, Roberto.
Afiliação
  • Leonart LP; Graduate Program in Pharmaceutical Sciences, Universidade Federal do Paraná, Curitiba, Paraná, Brazil.
  • Borba HHL; Department of Pharmacy, Universidade Federal do Paraná, Street Pref. Lothário Meissner, 632, Curitiba, Paraná, 80210-170, Brazil.
  • Ferreira VL; Graduate Program in Pharmaceutical Sciences, Universidade Federal do Paraná, Curitiba, Paraná, Brazil.
  • Riveros BS; Graduate Program in Pharmaceutical Sciences, Universidade Federal do Paraná, Curitiba, Paraná, Brazil.
  • Pontarolo R; Graduate Program in Pharmaceutical Sciences, Universidade Federal do Paraná, Curitiba, Paraná, Brazil. pontarolo@ufpr.br.
Pituitary ; 21(6): 642-652, 2018 Dec.
Article em En | MEDLINE | ID: mdl-30159696
PURPOSE: Acromegaly is a rare disease that results in the enlargement of body extremities and in organomegaly. Treatments include surgery, drugs, and radiotherapy, which are all onerous. Therefore, well-conducted cost-analyses are crucial in the decision-making process. METHODS: A systematic review of cost-effectiveness studies on acromegaly therapies was performed following PRISMA and Cochrane recommendations. The search for records was conducted in PubMed, Scopus, and Web of Science (May 2018). The quality of the included studies was assessed using the Joana Briggs Institute Tool. RESULTS: From initial 547 records, 16 studies were included in the review. The studies could present more than one economic evaluation, and encompassed cost-effectiveness (n = 13), cost-utility (n = 5), and cost-consequence (n = 1) analyses. All studies were model-based and evaluated only direct medical costs. Eleven records did not mention discounting and only 10 performed sensitivity analyses. The characteristic of the studies, the cost-effectiveness results and the studies' conclusions are described and commented upon. The main limitation of the studies was discussed and aspects to improve in future studies were pointed out. CONCLUSIONS: Cost-effectiveness studies on acromegaly have been performed in several scenarios, evaluating different phases of treatment. However, the studies present limitations and, overall, were considered of moderate quality. Further economic models should be developed following health economics guidelines recommendations, and must improve transparency.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Acromegalia Tipo de estudo: Guideline / Health_economic_evaluation / Prognostic_studies / Systematic_reviews Limite: Humans Idioma: En Revista: Pituitary Assunto da revista: ENDOCRINOLOGIA Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Brasil País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Acromegalia Tipo de estudo: Guideline / Health_economic_evaluation / Prognostic_studies / Systematic_reviews Limite: Humans Idioma: En Revista: Pituitary Assunto da revista: ENDOCRINOLOGIA Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Brasil País de publicação: Estados Unidos